Clinical Features and Risk Factors of Rapidly Progressive Systemic Sclerosis in a Single Center in China: Anti-RNA Polymerase III Antibodies as a Predictor

被引:1
|
作者
Yu, Qiuxia [1 ,2 ]
Zhang, Jin [1 ,2 ]
Fan, Liyi [3 ]
Yu, Tianhang [3 ]
Liu, Bingbing [1 ,2 ]
Ding, Jian [1 ,2 ]
机构
[1] Lihuili Hosp, Ningbo Med Ctr, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[2] Ningbo Univ, Li Huili Hosp, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[3] Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China
关键词
rapidly progressive systemic sclerosis; clinical characteristics; predictors; anti-RNA polymerase III antibodies; malignancy; AUTOANTIBODIES; INVOLVEMENT;
D O I
10.24976/Discov.Med.202335175.20
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: Systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extend of skin thickening. In this study, we classified a novel subset of SSc defined rapidly progressive systemic sclerosis (RPSSc), which based on the rate of skin thickening progression and the progressive of interstitial lung disease (ILD). We aimed to evaluate RPSSc clinical characteristics and predictive factors in a Chinese single center. Method: Overall, 75 patients diagnosed with SSc, classified into RPSSc (n = 14) and non-rapidly progressive SSc (non-RPSSc, n = 61) were retrospectively included in the study. Clinical characteristics, disease severity and autoantibodies were collected. Logistic regression, least absolute shrinkage, and selection operator (LASSO) regression analysis was used to identify RPSSc predictors. Receiver operating characteristic (ROC) analysis and Delong test was conducted to evaluate and compare different indexes.Results: RPSSc rate was 18.7%. ILD (64.3%), cardiac involvement (42.9%) were the most common organ system involvement of RPSSc, while Raynaud's phenomenon incidence significantly decreased. Disease duration (12 vs 72, months), sex (42.9% vs 11.5%, male %), SSc subset (85.7% vs 27.9%, diffuse cutaneous SSc (dsSSc) %), modified Rodnan total skin score (mRSS) (20.5 vs 6), Raynaud's phenomenon (64.3% vs 98.4%), cardiac involvement (42.9% vs 18%), higher incidence with malignancy (28.6% vs 1.6%) and positive anti-RNA polymerase III antibodies (ARA) (64.3% vs 1.6%) were statistically significant differences among the RPSSc groups and non-RPSSc groups (p < 0.05). Univariate analysis showed that positive ARA, male, dsSSc and malignancy were RPSSc risk factors, while long-disease duration, Raynaud's phenomenon was RPSSc protective factors. ARA was the strongest factor associated to RPSSc (OR 108, 95% CI 11.287-1033.327, p < 0.001). LASSO logistic regression model identified six factors: Disease duration, dsSSc, malignancy, cardiac involvement, positivity of ARA were RPSSc risk factors, Raynaud's phenomenon was RPSSc protective factors.Conclusions: RPSSc is an SSc clinical category which should be accounted for early detection of organ involvement and close follow-up of malignancy. ARA might be used as a predictor for RPSSc and organ involvement.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 50 条
  • [1] Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies
    Motegi, Sei-ichiro
    Toki, Sayaka
    Yamada, Kazuya
    Uchiyama, Akihiko
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2015, 42 (02): : 189 - 192
  • [2] Clinical features of 11 patients affected by systemic sclerosis with anti-RNA polymerase III antibodies
    Cavazzana, I.
    Ceribelli, A.
    Scarsi, M.
    Airo, P.
    Cattaneo, R.
    Tincani, A.
    Franceschini, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A6 - A6
  • [3] Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain
    Callejas-Moraga, E. L.
    Guillen-Del-Castillo, A.
    Marin-Sanchez, A. M.
    Roca-Herrera, M.
    Balada, E.
    Tolosa-Vilella, C.
    Fonollosa-Pla, V.
    Simeon-Aznar, C. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : S41 - S48
  • [4] Anti-RNA polymerase antibodies in Korean patients with systemic sclerosis and their association with clinical features
    Kang, EH
    Lee, EB
    Kim, DJ
    Im, CH
    Lee, HJ
    Song, YW
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (05) : 731 - 732
  • [5] The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy
    Kodera, Masanari
    Tanaka, Yoshihito
    Ito, Yumi
    Sugata, Miho
    Hisada, Satoko
    Ichiki, Naohisa
    Tanabe, Toshiaki
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis
    Harvey, GR
    Butts, S
    Rands, AL
    Patel, Y
    McHugh, NJ
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 117 (02): : 395 - 402
  • [7] Rapidly progressive systemic sclerosis associated with breast carcinoma: Report of a case with anti-RNA polymerase III antibody
    Honma, Masaru
    Komatsu, Shigetsuna
    Igawa, Satomi
    Murakami, Masamoto
    Iizuka, Hajime
    JOURNAL OF DERMATOLOGY, 2012, 39 (06): : 574 - 576
  • [8] Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies
    Monfort, J. -B.
    Mathian, A.
    Amoura, Z.
    Frances, C.
    Barbaud, A.
    Senet, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (01): : 33 - 36
  • [9] Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients
    Liu, C.
    Hou, Y.
    Xu, D.
    Li, L.
    Zhang, Y.
    Cheng, L.
    Zhang, F.
    Li, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 929 - 930
  • [10] Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis
    Wielosz, Ewa
    Dryglewska, Magdalena
    Majdan, Maria
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (06): : 909 - 914